Looking to rebuild physician confidence in Byetta injection, Amylin (AMLN-$19.69) and Lilly (LLY-$35.70) directed much of their lecture and lobbying time at the 2010 ADA conference addressing safety and tolerability issues that have dogged their type-2 diabetes treatment since soon after its June 2005 launch.Presentations at the Orlando meeting showed Byetta-treated patients were at no higher risk for renal or pancreatic problems than existing treatments — including, Merck’s oral Januvia and Novo Nordisk’s in-kind Victoza injection therapy. Ergo, with no new sense of urgency for Byetta use – all Amylin and Lilly accomplished was to provide additional motivation for physicians to prescribe challengers Januvia and Victoza….
Continue Reading ….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment